FDA approves J&J’s TECNIS PureSee intraocular lens
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
MassDevice
Johnson & Johnson wins FDA nod for new intraocular lens
Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.
Healio
FDA approves Johnson & Johnson’s Tecnis PureSee IOL
The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
BioSpace
Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts
Psychedelics are a “game changer” in depression care, according to William Blair, but the complicated treatment regimens mean ...
AOL
US FDA approves Eton Pharma's hormonal disorder drug
FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kell/File Photo Feb 25 (Reuters) - The ‌U.S. Food ...
Morningstar
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood ...
Science Daily
Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia
Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common ...
AOL
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...
Nasdaq
Johnson & Johnson: FDA Approves Monthly Dosing Schedule For RYBREVANT FASPRO
(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved a simplified monthly dosing schedule for RYBREVANT FASPRO or amivantamab and hyaluronidase-lpuj. The milestone builds upon the recent ...
Benzinga.com
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner
The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s (NYSE: JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj).
Cure Today
FDA Approves Filkri Biosimilar to Prevent Neutropenia in Blood Cancer
FDA approves Filkri, a biosimilar that helps reduce infection risk and speed white blood cell recovery during chemotherapy and other treatments. The U.S. Food and Drug Administration (FDA) has ...